Anita Sivam, DO
Allergy & Immunology · Zionsville, INNPI 1134547037
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (49.4%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. Alk-abello, Inc accounts for 76.1% of it on its own, with 16 other manufacturers making up the rest. Reporting peaked in 2022 at $7,035 and has fallen 95.6% since, to $309 in 2025.
Across 88 payments — averaging $103.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alk-abello, Inc$7K
- Sanofi$727
- GSK$442
- AstraZeneca$333
- Regeneron Healthcare Solutions, Inc.$161
- Sanofi-aventis U.S. LLC$123
- plus $393 from 11 others
What the payments were for
- Speaking & faculty fees$4,50049%
- Grants$4004%
- Travel & lodging$1,91221%
- Food & beverage$2,17424%
- Education$1231%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alk-abello, Inc | 14 | $6,929 |
| Sanofi | 13 | $727 |
| GSK | 21 | $442 |
| AstraZeneca | 10 | $333 |
| Regeneron Healthcare Solutions, Inc. | 8 | $161 |
| Sanofi-aventis U.S. LLC | 2 | $123 |
| Pfizer | 4 | $72 |
| Novartis | 4 | $64 |
| Amgen | 3 | $58 |
| Blueprint Medicines Corporation | 1 | $54 |
| Optinose US, Inc. | 2 | $39 |
| Biocryst US Sales Co., LLC | 1 | $20 |
| Bio Products Laboratory USA, Inc. | 1 | $20 |
| ARS Pharmaceuticals Operations, Inc. | 1 | $18 |
| CSL Behring | 1 | $16 |
| Genentech USA, Inc. | 1 | $16 |
| Hikma Pharmaceuticals USA | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$9,109 in reported general payments places this provider in the 70th percentile of 49 allergy & immunology providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Dupixent PenDupilumab | 17 | $85,682 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 66 | $46,474 |
| Gamunex-CImmune Globul G/Gly/Iga Avg 46 | 13 | $38,326 |
| Spiriva RespimatTiotropium Bromide | 25 | $15,244 |
| Epinephrine | 84 | $12,970 |
| Breo ElliptaFluticasone/Vilanterol | 12 | $11,427 |
| SymbicortBudesonide/Formoterol Fumarate | 17 | $8,200 |
| Advair HfaFluticasone Propion/Salmeterol | 20 | $8,141 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 22 | $6,824 |
| Azelastine Hcl | 144 | $4,582 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 19 | $2,939 |
| Levocetirizine Dihydrochloride | 230 | $2,553 |
| Montelukast Sodium | 244 | $1,821 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 56 | $1,492 |
| Ipratropium Bromide | 33 | $1,454 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta | $442 | $57,90178 claims |
| Hikma Pharmaceuticals USAEpinephrine | $15 | $12,97084 claims |
| AstraZenecaSymbicort | $333 | $8,20017 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 49 allergy & immunology providers in Indiana.
Other allergy & immunology in Zionsville
- Ann EsquivelZionsville$8K
- Vivian NanagasZionsville$288
- Nabeel FarooquiFishers$1.2M
- David PattersonNoblesville$252K
- William SmitsFort Wayne$203K
- Steven WiseIndianapolis$137K
- Majed KoleilatEvansville$122K
- Pinkus GoldbergIndianapolis$89K
- Douglas NeeldFort Wayne$77K
- Pooja PatelMerrillville$55K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.